Latest news with #metabolicdisease
Wall Street Journal
2 days ago
- Health
- Wall Street Journal
RFK Jr. Can Take On America's Addiction to Carbs
Health and Human Services Secretary Robert F. Kennedy Jr. says he wants to 'make America healthy again.' With HHS updating its Dietary Guidelines for Americans this year, now is his chance. Nearly all Americans are at risk for metabolic disease. It's time to recommend for them the lower-carb diet. The Dietary Guidelines for Americans are reviewed every five years to advise on what to eat to prevent chronic disease. They were first released in 1980, yet the U.S. obesity rate has tripled since then.
Yahoo
02-06-2025
- Business
- Yahoo
Umbrella Labs Expands Research Portfolio with Availability of Retatrutide (LY3437943), a Next-Generation Triple Agonist Peptide
TUCSON, AZ / / June 2, 2025 / Umbrella Labs, a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943), an investigational triple agonist peptide developed for use in scientific and academic research. This addition marks a significant milestone in the company's commitment to supporting cutting-edge research in metabolic disease, obesity, and type 2 diabetes mellitus (T2DM). Retatrutide has gained attention within the scientific community due to its unique ability to activate three key receptors involved in metabolic regulation: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-receptor mechanism offers a promising new direction for researchers investigating novel treatments for obesity-related diseases. "We are proud to offer Retatrutide as part of our mission to provide academic and institutional researchers with the most innovative compounds available," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "The peptide's clinical and preclinical data demonstrate its potential as a transformative research molecule." Scientific Highlights: Preclinical and Clinical Validation In comparative rodent studies, Retatrutide outperformed GLP-1 monotherapy and the dual agonist Tirzepatide, producing over 30% weight reduction while improving liver lipid profiles, insulin sensitivity, and inflammatory markers (Ma et al., 2025). A Phase 2 human trial led by Jastreboff et al. (2023) demonstrated up to 24.2% weight loss in non-diabetic obese participants, along with significant improvements in blood pressure, fasting glucose, LDL cholesterol, and HbA1c. These outcomes exceed the performance benchmarks of currently approved GLP-1-based therapeutics, including semaglutide. Expanding Research Horizons: Metabolic, Hepatic, and Cardiovascular Implications Retatrutide's diverse effects have fueled interest in multiple areas of academic investigation: Obesity and Weight Management: The triple receptor action mimics metabolic responses seen in bariatric surgery, with non-invasive delivery. T2DM Research: Demonstrated reductions in HbA1c (up to 2.2%) and possible β-cell preservation. NAFLD/NASH Models: Reduction in hepatic fat, ALT/AST normalization, and improved lipid oxidation suggest promising utility. Cardiovascular Metrics: Lower CRP and triglycerides, with HDL elevation, signal potential long-term cardiac benefit. Emerging exploratory areas include microdosing studies in appetite regulation, mitochondrial function, and speculative neuroendocrine roles due to GLP-1 expression in the central nervous system. Commitment to Quality: Umbrella Labs as a Trusted Supplier Retatrutide remains an investigational compound not approved for human use and is offered strictly for in vitro and animal-based research by qualified institutions. Umbrella Labs ensures cGMP-compliant manufacturing, third-party analytical testing, and reliable batch documentation for all peptides. Researchers interested in sourcing Retatrutide can find the compound listed at:Buy Retatrutide (LY3437943) - Umbrella Labs For additional research peptides and SARMs, visit the Umbrella Labs homepage. About Umbrella Labs Umbrella Labs is a premier supplier of research-grade peptides, SARMs, and other investigational compounds used by universities, pharmaceutical developers, and independent research teams. With a focus on purity, testing transparency, and customer support, Umbrella Labs continues to lead the field in supplying next-generation biochemicals for science-driven innovation. Media Contact Samuel YannerDirector of Scientific OperationsUmbrella Labs1-866-289-7276support@ E Hemisphere Loop, Tucson, AZ 85706 References Coskun T, Sloop KW, Loghin C, et al. LY3437943, a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Improves Metabolic Parameters in Preclinical Models of Obesity. Cell Metab. 2018;28(5):710-722.e10. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple-hormone-receptor agonist Retatrutide in adults with obesity: a randomized, double-blind, phase 2 trial. N Engl J Med. 2023;389(13):1134-1145. Ma X, Zhang L, Su Y, et al. Comparative efficacy of GLP-1/GIP/glucagon receptor agonism in diabetic mice: insights into Retatrutide's hepatometabolic benefits. J Endocrinol Invest. 2025;48(1):55-66. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. Killion EA, Wang J, Yie J, et al. Glucagon receptor activation increases energy expenditure and modulates lipoprotein metabolism in mice. Proc Natl Acad Sci USA. 2018;115(5):E1051-E1060. SOURCE: Umbrella Labs View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
15-05-2025
- Health
- CBS News
Baby treated with gene editing therapy for the first time by a team of Philadelphia doctors
A child diagnosed with a rare genetic disorder was successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of Philadelphia and Penn Medicine in a historical medical breakthrough. The landmark study published in The New England Journal of Medicine showcases the power of customized gene editing therapy to treat patients with rare metabolic disease. Nine-month-old KJ Muldoon was the first patient to be treated with a gene editing technology customized for his rare disease. "In patients who have urea cycle disorders, they can't break down protein, and unfortunately, what happens is ammonia builds up, and ammonia can be toxic to the brain and cause permanent neurologic damage," Dr. Rebecca Ahrens-Nicklas, of CHOP, said. Quick action was needed for KJ, and his parents, Nicole and Kyle Muldoon, had to process a lot fast. "Our child is sick," Kyle Muldoon, of Delaware County, said. "We either have to get a liver transplant or give him this medicine that's never been given to anybody before, right? I mean, what an impossible decision to make." With the team at CHOP and Penn, they decided to try the gene therapy called CRISPR animation DNA, which edits out the original, defective DNA and replaces it with the altered, repaired sequence. "CRISPR, a gene editor, enters the nucleus of the cell. And in this case, we programmed it to go to the site of the genetic variant that is actually causing the disease in KJ," University of Pennsylvania Dr. Kiran Musunuru said. KJ Muldoon received the first infusion in February and has follow-up doses in March and April – and it's working. "This could revolutionize the way we treat rare disorders for patients who have limited or no other options," Ahrens-Nicklas said. Doctors said KJ's condition has improved significantly. "I just knew he was ready, like he was ready to fight," Kyle Muldoon said. "He's proven to us time and time again how stubborn and spunky he really is," Nicole Muldoon said. The Muldoons are looking forward to the family of five being able to take KJ home very soon. The CRISPR gene editing therapy has been used for other diseases like sickle cell, but this is the first time it's been customized for one patient.
